Pricing Log in Create free account

Emergent Biosolutions Inc. (EBS) vs Evolus, Inc. (EOLS)

Emergent Biosolutions Inc. and Evolus, Inc. are both Drug Manufacturers Specialty & Generic companies. Evolus, Inc. is the larger, with a market value of $448.8M against $300.8M — 1.5× the size. Evolus, Inc. grew revenue faster over the last twelve months: 13.9% against −17.7%. Evolus, Inc. has the higher net margin (−9.56% vs −40.2%) and the higher return on invested capital (−12.6% vs −17.5%). Across the 18 metrics below, Evolus, Inc. leads on 12 and Emergent Biosolutions Inc. on 6.

Valuation

Metric EBS EOLS Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.45
P/S 0.48 1.39 2.11
P/B 0.98 n/m 1.69
Price to free cash flow 1.59 n/m 15.98
EV/EBITDA n/m n/m 12.21
EV/Sales 0.99 1.98 2.79
Earnings yield (83.82%) (6.84%) (15.61%)
Free cash flow yield 62.92% (1.94%) 0.00%

Profitability

Metric EBS EOLS Drug Manufacturers Specialty & Generic median
Gross margin 48.42% 66.38% 53.51%
Operating margin (27.70%) (4.79%) 0.00%
Net margin (40.16%) (9.56%) (2.31%)
Free cash flow margin 29.89% (2.71%) 0.00%
Return on equity (58.21%) 93.47% (0.80%)
Return on assets (21.23%) (12.38%) (1.67%)
Return on invested capital (17.45%) (12.60%) 0.00%

Growth

Metric EBS EOLS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (17.72%) 13.87% 5.22%
EPS growth (last fiscal year) 125.83% 1.23% 42.91%
Revenue growth, 5-year CAGR (13.74%) 39.36% 7.24%
Net income growth, 5-year CAGR (29.64%) 0.00% 0.00%

Health

Metric EBS EOLS Drug Manufacturers Specialty & Generic median
Debt to equity 1.62 (4.15) 0.04
Current ratio 4.58 1.42 2.46
Net debt to EBITDA 1.76 (4.08) 1.01

Dividend

Metric EBS EOLS Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.47%
Payout ratio — — 0.28

Size

Metric EBS EOLS Drug Manufacturers Specialty & Generic median
Market cap 300.78m 448.82m 300.78m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack